BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 31613363)

  • 1. Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system.
    Schwartz S; Cornely OA; Hamed K; Marty FM; Maertens J; Rahav G; Herbrecht R; Heinz WJ
    Med Mycol; 2020 Jun; 58(4):417-424. PubMed ID: 31613363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species.
    Marty FM; Cornely OA; Mullane KM; Ostrosky-Zeichner L; Maher RM; Croos-Dabrera R; Lu Q; Lademacher C; Oren I; Schmitt-Hoffmann AH; Giladi M; Rahav G; Perfect JR
    Mycoses; 2018 Jul; 61(7):485-497. PubMed ID: 29611227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial.
    Perfect JR; Cornely OA; Heep M; Ostrosky-Zeichner L; Mullane KM; Maher R; Croos-Dabrera R; Lademacher C; Engelhardt M; Chen C; Marty FM
    Mycoses; 2018 Jul; 61(7):420-429. PubMed ID: 29570857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials.
    Andes DR; Ghannoum MA; Mukherjee PK; Kovanda LL; Lu Q; Jones ME; Santerre Henriksen A; Lademacher C; Hope WW
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections.
    Chitasombat MN; Kontoyiannis DP
    Expert Opin Pharmacother; 2015; 16(10):1543-58. PubMed ID: 26100603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breakthrough Invasive Fungal Infections on Isavuconazole Prophylaxis and Treatment: What Is Happening in the Real-World Setting?
    Fung M; Schwartz BS; Doernberg SB; Langelier C; Lo M; Graff L; Tan M; Logan AC; Chin-Hong P; Babik JM
    Clin Infect Dis; 2018 Sep; 67(7):1142-1143. PubMed ID: 29617983
    [No Abstract]   [Full Text] [Related]  

  • 7. [Current therapeutic options in invasive mycosis and potential therapeutic role of isavuconazole].
    Garcia-Vidal C
    Rev Iberoam Micol; 2018; 35(4):192-197. PubMed ID: 30455108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole.
    Kovanda LL; Marty FM; Maertens J; Desai AV; Lademacher C; Engelhardt M; Lu Q; Hope WW
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28289034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center.
    Van Matre ET; Evans SL; Mueller SW; MacLaren R; Fish DN; Kiser TH
    Ann Clin Microbiol Antimicrob; 2019 Mar; 18(1):13. PubMed ID: 30894179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole.
    Rausch CR; DiPippo AJ; Bose P; Kontoyiannis DP
    Clin Infect Dis; 2018 Oct; 67(10):1610-1613. PubMed ID: 29771293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi.
    Desai AV; Kovanda LL; Hope WW; Andes D; Mouton JW; Kowalski DL; Townsend RW; Mujais S; Bonate PL
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases.
    Kaindl T; Andes D; Engelhardt M; Saulay M; Larger P; Groll AH
    J Antimicrob Chemother; 2019 Mar; 74(3):761-767. PubMed ID: 30476108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isavuconazole Treatment of Invasive Fungal Sinusitis: A Post Hoc Analysis of the SECURE and VITAL Trials.
    Durand ML; Kitt TM; Song Y; Marty FM
    Clin Infect Dis; 2021 Sep; 73(6):e1380-e1383. PubMed ID: 33914864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections.
    Murrell D; Bossaer JB; Carico R; Harirforoosh S; Cluck D
    Int J Pharm Pract; 2017 Feb; 25(1):18-30. PubMed ID: 27569742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity.
    Ledoux MP; Denis J; Nivoix Y; Herbrecht R
    J Mycol Med; 2018 Mar; 28(1):15-22. PubMed ID: 29551442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isavuconazole for treatment of rare invasive fungal diseases.
    Cornely OA; Mullane KM; Ostrosky-Zeichner L; Maher RM; Croos-Dabrera R; Lu Q; Lademacher C; Perfect JR; Oren I; Schmitt-Hoffmann AH; Giladi M; Marty FM; Rahav G
    Mycoses; 2018 Aug; 61(8):518-533. PubMed ID: 29611246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isavuconazole: A New Option for the Management of Invasive Fungal Infections.
    Pettit NN; Carver PL
    Ann Pharmacother; 2015 Jul; 49(7):825-42. PubMed ID: 25940222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isavuconazole for the prophylaxis and treatment of invasive fungal disease: A single-center experience.
    Vu CA; Rana MM; Jacobs SE; Saunders-Hao P
    Transpl Infect Dis; 2021 Apr; 23(2):e13469. PubMed ID: 32946658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isavuconazole for the treatment of invasive fungal disease in patients receiving ibrutinib.
    Cummins KC; Cheng MP; Kubiak DW; Davids MS; Marty FM; Issa NC
    Leuk Lymphoma; 2019 Feb; 60(2):527-530. PubMed ID: 30037292
    [No Abstract]   [Full Text] [Related]  

  • 20. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.
    Marty FM; Ostrosky-Zeichner L; Cornely OA; Mullane KM; Perfect JR; Thompson GR; Alangaden GJ; Brown JM; Fredricks DN; Heinz WJ; Herbrecht R; Klimko N; Klyasova G; Maertens JA; Melinkeri SR; Oren I; Pappas PG; Ráčil Z; Rahav G; Santos R; Schwartz S; Vehreschild JJ; Young JH; Chetchotisakd P; Jaruratanasirikul S; Kanj SS; Engelhardt M; Kaufhold A; Ito M; Lee M; Sasse C; Maher RM; Zeiher B; Vehreschild MJGT;
    Lancet Infect Dis; 2016 Jul; 16(7):828-837. PubMed ID: 26969258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.